Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Wang, Kening

Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. [electronic resource] - Journal of virology 10 2017

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural

1098-5514

10.1128/JVI.00411-17 doi


AIDS Vaccines--immunology
Animals
Antibodies, Monoclonal--administration & dosage
Antibody-Dependent Cell Cytotoxicity--immunology
Cell Line
Eye Diseases--prevention & control
Female
HIV Envelope Protein gp120--genetics
Herpes Simplex--immunology
Humans
Killer Cells, Natural--immunology
Leukocytes, Mononuclear--immunology
Lymphocyte Activation--immunology
Mice
Mice, Inbred BALB C
Receptors, Tumor Necrosis Factor, Member 14--immunology
Simplexvirus--genetics
Viral Envelope Proteins--genetics